Clinical trial · Interventional
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
NCT03336216CI-TRIAL-00079061completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cabiralizumab | Biological | — | UNRESOLVED |
| Fluorouracil | Drug | Fluorouracil | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Irinotecan Hydrochloride | Drug | Irinotecan | ALIAS |
| Leucovorin | Drug | Leucovorin | ALIAS |
| Nab-paclitaxel | Drug | Nab-paclitaxel | ALIAS |
| Nivolumab | Biological | Nivolumab | ALIAS |
| Onivyde | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Arm A
- description
- Investigator choice of chemotherapy: Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)
- interventionNames
- Drug: Nab-paclitaxel
- Drug: Onivyde
- Drug: Fluorouracil
- Drug: Gemcitabine
- Drug: Leucovorin
- Drug: Irinotecan Hydrochloride
- type
- EXPERIMENTAL
- label
- Arm B
- description
- Cabiralizumab Q2W + Nivolumab Q4W
- interventionNames
- Biological: Cabiralizumab
- Biological: Nivolumab
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy * ECOG Performance status 0-1 * Adequate organ functions * Measurable disease Exclusion Criteria: * Suspected or known CNS metastasis * Participants with active, known, or suspected autoimmune disease * Uncontrolled or significant cardiovascular disease * Prior exposure to selected immune cell-modulating antibody regimens
References
Publications (0)
Data not yet available
No reference posted for this study.